Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells 3,174 Shares of Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 3,174 shares of the company's stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $261.61, for a total transaction of $830,350.14. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

John Oyler also recently made the following trade(s):

• On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The shares were sold at an average price of $256.49, for a total value of $374,475.40.
• On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The stock was sold at an average price of $266.05, for a total value of $979,064.00.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The shares were sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Trading Down 5.2%

Shares of ONC stock traded down $13.29 during trading hours on Friday, reaching $241.20. 400,801 shares of the stock were exchanged, compared to its average volume of 340,778. The company has a market cap of $26.44 billion, a price-to-earnings ratio of -64.84 and a beta of 0.30. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $141.84 and a 12-month high of $287.88. The stock's 50-day moving average is $247.90. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. On average, sell-side analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ONC. Bank of America upgraded BeOne Medicines from a "neutral" rating to a "buy" rating and increased their target price for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. TD Securities reiterated a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a research report on Thursday, April 24th. Royal Bank Of Canada raised shares of BeOne Medicines from an "outperform" rating to a "moderate buy" rating and set a $311.00 price objective for the company in a research note on Friday. JPMorgan Chase & Co. boosted their target price on shares of BeOne Medicines from $317.00 to $321.00 and gave the stock an "overweight" rating in a report on Friday. Finally, Macquarie increased their price target on shares of BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $320.67.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.